First Trust Direct Indexing L.P. Grows Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

First Trust Direct Indexing L.P. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 13.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,898 shares of the biopharmaceutical company’s stock after purchasing an additional 340 shares during the period. First Trust Direct Indexing L.P.’s holdings in Alnylam Pharmaceuticals were worth $555,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Mach 1 Financial Group LLC acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $841,000. Gilbert & Cook Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 7.7% during the 4th quarter. Gilbert & Cook Inc. now owns 4,443 shares of the biopharmaceutical company’s stock valued at $850,000 after buying an additional 317 shares during the period. Truist Financial Corp purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $474,000. Semanteon Capital Management LP purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth $308,000. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new position in Alnylam Pharmaceuticals in the 4th quarter valued at about $416,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ALNY. Wolfe Research assumed coverage on Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They set a “peer perform” rating on the stock. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Royal Bank of Canada restated an “outperform” rating and issued a $235.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. HC Wainwright reissued a “buy” rating and set a $395.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, March 5th. Finally, Needham & Company LLC restated a “buy” rating and issued a $200.00 target price on shares of Alnylam Pharmaceuticals in a research note on Thursday. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $215.88.

Alnylam Pharmaceuticals Stock Up 1.3 %

Shares of Alnylam Pharmaceuticals stock opened at $152.33 on Monday. The business has a fifty day simple moving average of $149.65 and a 200-day simple moving average of $165.14. The firm has a market cap of $19.19 billion, a price-to-earnings ratio of -56.84 and a beta of 0.41. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. During the same period in the prior year, the firm earned ($1.40) EPS. The business’s revenue for the quarter was up 54.8% on a year-over-year basis. Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -4.43 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.